Samsung Biologics has completed the acquisition of a biopharmaceutical manufacturing facility located in Rockville, Maryland, in the United States. With this acquisition, the company has secured its first production base in the U.S., further strengthening its global CDMO (Contract Development and Manufacturing Organization) competitiveness.

The newly acquired Rockville facility has a capacity of 60,000 liters (L). Combined with the existing capacity of its Incheon headquarters campus, Samsung Biologics’ total global production capacity has increased to 845,000 liters.

Through integration of the Incheon and Rockville sites, Samsung Biologics plans to maintain a stable supply of existing products while actively expanding new contract orders. The company is also considering additional investment to expand production capacity and advance technologies at the Rockville facility, taking into account medium- to long-term demand and utilization levels.

John Rim, CEO of Samsung Biologics, said, “This acquisition represents meaningful progress in expanding our global manufacturing footprint,” adding, “Together with the professional workforce at the Rockville facility, we will maintain operational continuity and ensure a stable supply system.”

Samsung Biologics plans to use the securing of this U.S. production base as a springboard to enhance responsiveness to North American clients and further expand its presence in the global biopharmaceutical market.

Popular News